Prairie Vascular Research Network, Regina, Saskatchewan Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2014
NCT01930591
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

clopidogrel (plavix) (1 trial)

ticagrelor (brilinta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2